Abstract Activated protein C (APC) acts as a potent anticoagulant enzyme by inactivating Factor V and Factor VIII. In this study, protein S was shown to increase the inactivation of purified Factor VIII by APC ninefold. The reaction rate was saturated with respect to the concentration of protein S when protein S was present in a 10-fold molar excess over APC. The heavy chain of Factor VIII was cleaved by APC and protein S did not alter the degradation pattern. Factor VIII circulates in a complex with the adhesive protein von Willebrand factor. When purified Factor VIII was recombined with von Willebrand factor, the inactivation of Factor VIII by APC proceeded at a 10-20-fold slower rate as compared with Factor VIII in the absence of von Willebrand factor. Protein S had no effect on the inactivation of the Factor VIII-von Willebrand factor complex by APC. After treatment of this complex with thrombin, however, the actions of APC and protein S towards Factor VIII were completely restored. In hemophilia A plasma, purified Factor VIII associated with endogenous von Willebrand factor, resulting in a complete protection against APC (4 nM). By mixing hemophilic plasma with plasma from a patient with severe von Willebrand's disease, we could vary the amount of von Willebrand factor. 1 U of von Willebrand factor was needed to provide protection of 1 U Factor VIII. Also in plasma from patients with the IIA-type variant of von Willebrand's disease, Factor VIII was protected. In von Willebrand's disease plasma, which was depleted of protein S., APC did not inactivate Factor VIII. These results indicate that protein S serves as a cofactor in the inactivation of Factor VIII and Factor VIIIa by APC and that von Willebrand factor can regulate the action of these two anticoagulant proteins.
Introduction
Over the past few years, activated protein C (APC)' has become recognized as an important naturally occurring anticoagulant enzyme (1) . It exerts its effect by inactivating the cofactors Factor V and Factor VIII (2-7.) and by stimulating fibrinolysis (8, 9) . This anticoagulant pathway is regulated in several ways. Activation of the vitamin K-dependent zymogen protein C by thrombin is greatly enhanced by thrombomodu-lin, a protein cofactor located on the surface of endothelial cells (10, 11) . Factor Va also stimulates the activation of protein C (12) . Optimal inactivation of Factor Va by APC is achieved only in the presence of phospholipid, Ca2", and protein S (2, 3, 13) . Protein S is a vitamin K-dependent cofactor of APC. The availability of protein S is diminished by its binding to C4b-binding protein, a regulatory protein of the complement system (14, 15) . APC itselfis cleared from the circulation by protein C inhibitor, the inhibitor ofAPC (16) . Cell surfaces of platelets (17) and endothelial cells (18) have been implied as being capable of promoting Factor Va inactivation by assembling the protein S-APC complex. On the other hand, the inactivation reaction is inhibited by Factor Xa (16, 19, 20) . Similarly, Factor IX/IXa was found to protect Factor VIIIa or Factor VIII against inactivation by APC (21, 22). It has also been shown that the thrombin-ictivated forms of Factor V (13, 19, 20) and Factor VIII (5, 23) are inactivated more rapidly than their precursors. This last finding is of interest because activation of Factor VIII is accompanied by its release from von Willebrand factor (24) , a plasma glycoprotein ofhigh molecular weight that mediates the adhesion of platelets to vascular endothelium (25). Lack of von Willebrand factor or increased electrophoretic mobility of the multimeric protein have been correlated with a decreased stability of Factor VIII in plasma (26) . These observations have prompted us to investigate the role of von Willebrand factor in regulating the inactivation of Factor VIII/VIIIa by APC. Here we report that in the presence of von Willebrand factor, Factor VIII is protected against inactivation by APC.
Methods
Materials. Human plasma concentrate containing vitamin K-dependent proteins and Factor VIII concentrates were kindly provided by Dr. J. Over, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam. Factor VIII concentrates (Hyland Hemofil HT) were also purchased from Travenol Laboratories, Inc. (Munchen, FRG). Sephadex G-25, G-75, and G-200, Sepharose CL-4B, QAE-Sephadex, Blue Sepharose, heparin Sepharose, CNBractivated Sepharose 4B, and mono S and mono Q ion-exchange columns together with the fast protein liquid chromatography system were purchased from Pharmacia Biotechnology (Uppsala, Sweden).
Enzymological iodination reagent was obtained from Bio-Rad Laboratories (Richmond, CA). Chromogenic substrates S2238 (H-D-Phe-pipecolyl-Arg-p-nitroaniline) and S2366 (L-pyroGlu-Pro-Arg-p-nitroaniline) and the Coatest Factor VIII assay were from KabiVitrum (Stockholm, Sweden). Na'25I (sp act 14 mCi/jig iodine) was from Amersham (Buckinghamshire, UK). Centricon 30 ultrafiltration membranes were from Amicon Corp. (Danvers, MA). Cephalin and kaolin were from Boehringer Mannheim (Mannheim, FRG). Rabbit brain thromboplastin was from Dade American (Aguada, Puerto Rico). Factor V-deficient plasma was from Merz+Dade AG (Dudingen, Switzerland). Plasmas deficient in Factor VIII (Factor VIII:C < 0.01 U/ml, VWF:Ag = 1.2 U/ml) and von Willebrand factor (Factor VIII:C < 0.01 U/ml, VWF:Ag < 0.0004 U/ml) were from patients of our hospital. These plasmas contained undetectable amounts ofFactor VIII antigen (23) . Protein S antigen in these plasmas was 89 and 92%, respectively. Factor V concentration in these plasmas was 100 and 72%, respectively. Patients with type IIA von Willebrand's disease were diagnosed by means ofa decreased ristocetin cofactor activity (27) and lack of high molecular weight multimers (28) . Peroxidase-conjugated rabbit anti-von Willebrand factor antibody was from Dako Corp. (Copenhagen, Denmark). Antibodies against von Willebrand factor, protein C, and protein S were raised in goats or rabbits using standard procedures. Rabbit anti-C4b-binding protein antiserum was from Calbiochem-Behring Corp. (San Diego, CA). BSA, soybean trypsin inhibitor, diisopropylfluorophosphate, phenylmethanesulfonylfluoride, human a-thrombin (3417 U/ml), hirudin and Echis carinatus venom (Ecarin) were obtained from Sigma Chemical Co. (St. Louis, MO). All other reagents were of the highest grade available.
Proteins. Human Factor VIII was purified from commercial concentrates of two different origins (see Materials). The procedure was essentially the same for both preparations and has been described elsewhere (23) . The resulting Factor VIII had a specific activity of 8,000 U/mg and could be activated fivefold with thrombin (0.05 U/ml). It was stored at -20'C in Michaelis buffer (28.5 mM sodium acetate, 28.5 mM sodium barbital, 116 mM NaCl, pH 7.35) containing 2 mM CaCl2 and 3 mg/ml BSA (fatty acid free, treated with 1 mM diisopropylfluorophosphate and 1 mM iodoacetic acid). Radioiodination of Factor VIII was carried out with the lactoperoxidase/glucose oxidase method (29) . Factor VIII activity was determined using a onestage clotting assay (30, 31) (23) . The specific activity of the preparation was 100 VWF:Ag U/mg. Factor VIII-von Willebrand factor complex was prepared by mixing purified Factor VIII (5 U) with von Willebrand factor (17 U VWF:Ag) followed by removing CaC12 by spinning the mixture through a Centricon 30 microconcentrator and reconstituting the complex in Michaelis buffer containing 3 mg/ml BSA (fatty acid free).
Protein C, protein S, and prothrombin were purified from a human plasma concentrate containing the vitamin K-dependent proteins. Throughout the procedure, the proteins were measured by rocket immunoelectrophoresis (32). 20 bottles of concentrate were dissolved in 400 ml 0.1 M trisodium citrate, 25 mM benzamidine-HCl, pH 8.0. After the addition of 40 mg of soybean trypsin inhibitor, this was incubated for 30 min at 37°C. All following steps (except FPLC) were performed at 4°C. A barium citrate precipitate was obtained by slowly adding 80 ml of 1 M BaC12. The precipitate was washed with 0.1 M BaCI2, 25 mM benzamidine-HCl, pH 8.0, and with 25 mM benzamidine-HCl, respectively, followed by differential precipitation with 33-70% (vol/vol) saturated ammonium sulfate. The final precipitate was dissolved and subjected to ion-exchange chromatography on a QAE-Sephadex column (5 X 20 cm), equilibrated with MES-buffer (10 mM MES, 150 mM NaCl, 10 mM EDTA, 0.02% sodium azide, pH 6.0). After washing with starting buffer, the proteins were eluted with a linear gradient of NaCl (0.15 to 0.5 M in MES buffer, 1,200 ml in each chamber). Protein C and protein S eluted just ahead of prothrombin, which constituted the majority of protein. Prothrombin was further purified by affinity chromatography on heparin-Sepharose as described earlier (33) . The QAE-Sephadex fractions containing protein C and protein S were pooled, concentrated threefold in a dialysis bag using Sephadex G-200 and dialyzed. Further purification of protein C and protein S was achieved by consecutive chromatography on Blue Sepharose CL-6B (2.5 X 19 cm in 50 mM Tris-HCl, 150 mM NaCI, 2 mM EDTA, 0.02% sodium azide, pH 7.4) and heparin-Sepharose CL-6B (2.5 X 7 cm in 50 mM Imidazol, 50 mM NaCl, 2.5 mM CaCl2, 2 mM benzamidine-HCl, 0.02% sodium azide, pH 6.0). Protein C and protein S were recovered as two overlapping peaks from the Blue Sepharose column. Protein S did not bind to the Blue Sepharose column, while protein C was slightly retarded. Remaining prothrombin bound to this column. Heparin-Sepharose chromatography resulted in complete separation of protein C and protein S. Protein S had no affinity to the heparin-Sepharose column, while protein C was eluted during extensive washing with starting buffer. In some cases, traces of contaminants were removed and the proteins were concentrated using mono Q ion-exchange FPLC in 50 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA, 0.02% sodium azide, pH 7.4 and a linear gradient ofNaCl (0.15 to 0.5 M). The proteins were stored at -70'C and were stable for at least 2 mo. Repeated freeze-thawing was avoided. On SDS PAGE (34), both protein C and protein S appeared > 95% homogeneous.
Protein C showed a single band of M, 62,000 and two bands of M, 43,000 and Mr 28,000 upon reduction. Protein S showed a band of M, 69,000 without reduction. Protein C was activated using thrombinSepharose beads. For that purpose, prothrombin (74 mg) was activated at 37°C in 10 ml 0.1 M NaHCO3, 0.5 M NaCI, pH 8.4, with 0.11 U Echis carinatus venom. Thrombin activity was monitored with the chromogenic substrate S2238 at a concentration of 0.2 mM in 50 mM Tris-HCI, 150 mM NaCl, 0.5 mg/ml bovine serum albumin, pH 7.8. After maximal activation, the mixture was coupled to 7 g CNBr-activated Sepharose 4B according to the manufacturer's instructions. Concomitant coupling of the snake venom had no effect on the activity of the thrombin-Sepharose. Protein C (400 Mg) was activated with 0.5 ml thrombin-Sepharose in 50 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA, 0.02% sodium azide, pH 7.4 at 37°C. The activation was followed by measuring the amidolytic activity with 0.4 mM S2366 as substrate. At maximum activation the thrombin-Sepharose was spun down and washed with Tris-buffer. The supernatant and the washes were applied to a mono Q column as described above to remove traces of thrombin. APC was stable for at least 2 mo when stored at -70°C.
Protein S and C4b-binding protein deficient plasma was prepared from plasma ofa patient with severe von Willebrand's disease. For this purpose, 20 ml of plasma was passed over two columns, containing 140 mg anti-C4b-binding protein immunoglobulin from rabbit antiserum coupled to 10 g CNBr-activated Sepharose 4B and 27 mg of immunopurified goat anti-protein S immunoglobulin coupled to 3 g CNBr-activated Sepharose 4B, respectively. Rocket immunoelectrophoresis (32) showed no detectable protein S and C4b-binding protein antigens (< 2%) in the eluate. Factor V activity was determined by means of the prothrombin time in Factor V-deficient plasma.
SDS polyacrylamide slab gel electrophoresis (34) was carried out with 3-25% gradient gels. Protein concentrations were determined colorimetrically (35) using BSA as a standard.
Inactivation ofFactor VIII in a purified system. Factor VIII (final concentration 3 U/ml, 1.2 nM, based upon a plasma concentration of 0.1 g/ml and an average molecular weight of 250,000 D) was preincubated for 5 min at 20°C with cephalin (8 ,g/ml, treated with 1 mM phenylmethanesulfonylfluoride) in Michaelis buffer, pH 7.35 containing 3 mg/ml BSA, 1 U/mI hirudin and 5 mM CaCI2. Then APC (4 nM) was added together with increasing amounts of protein S (0-240 nM) in a final volume of 110 ,ul. 10-l aliquots were withdrawn at different times, diluted 50-fold with ice-cold Michaelis buffer and immediately assayed for Factor VIII coagulant activity. Once diluted, the Factor VIII activity was stable for at least 30 min.
In another set of experiments, Factor VIII-von Willebrand factor complex (containing 2 U/ml Factor VIII and 4 U/ml VWF:Ag) was incubated with cephalin (8 jg/ml), APC (3 nM) with or without protein S (22 nM). Before the incubation, Factor VIII-von Willebrand factor complex was incubated with thrombin (0.05 U/ml) for 3 min at Inactivation ofFactor VIII by Activated Protein C 1237 20'C. This resulted in a sevenfold activation of Factor VIII. After addition ofhirudin (1 U/ml), Factor VIIIa was stable at 4VC for at least 2 h. Otherwise, the conditions were as described above.
Proteolysis of Factor VIII by APC with or without protein S was investigated by substituting '25I-Factor VIII (0.4 U/ml, 0.4 MCi/ml) for Factor VIII. After 20 min of incubation at 20'C, a 40-Ml aliquot was withdrawn and added to 20 Al sample buffer that contained 4% (wt/ vol) SDS and 10% (vol/vol) P-mercaptoethanol. The samples were boiled for 5 min and subjected to SDS polyacrylamide slab gel electrophoresis followed by autoradiography using Kodak X-omat AR5 film and Dupont Cronex Lightening Plus intensifying screens (DuPont Co., Wilmington, DE). Inactivation ofFactor VIII in plasma. Factor VIII (0.15 U/ml, final concentration) or Factor VIII-von Willebrand factor complex (containing 0.3 U/ml VWF:Ag) were added to 100 AI ofeither hemophilia A plasma, von Willebrand's disease plasma or von Willebrand's disease plasma immunodepleted of protein S and C4b-binding protein (see above). Cephalin (4 Mg/ml) and Michaelis buffer containing bovine serum albumin were added to obtain a calcium concentration of2 mM and 0.5 U/ml hirudin in a final volume of 200 ul. After a preincubation of 5 min at 37°C, APC and protein S were added at the indicated concentrations and at different times at 37°C, 30-Ml aliquots were removed, diluted 25-fold in ice-cold buffer and remaining Factor VIII activity was measured using the Coatest chromogenic assay. The one-stage coagulation assay could not be used in these experiments, because too high dilutions of the aliquots were needed to abolish the effect of APC on the coagulation assay. In the same aliquots, the amidolytic activity of APC was measured with the chromogenic substrate S2366.
Gefliltration ofFactor VIII-von Willebrandfactor complexes. Factor VIII (-0.6 U) was mixed with various amounts ofvon Willebrand factor and applied to a Sepharose CL-4B column (0.8 X 20 cm), which was equilibrated in Michaelis buffer containing 4% (wt/vol) BSA and 0.005% Triton X-100. Fractions of 300 Ml were collected at a flow rate of2 ml/h at 4°C and assayed for Factor VIII coagulant activity and von Willebrand factor antigen. The fraction containing the highest Factor VIII concentration was diluted to a final concentration of 0.6 U/ml Factor VIII and incubated with APC (4 nM) in the presence of4 Ag/ml cephalin and 5 mM CaCl2. Factor VIII activity at different timepoints was determined as described above for the inactivation of Factor VIII in plasma.
Results
Inactivation ofFactor VIII in a purified system. The inactivation of Factor VIII by APC is shown in Fig. 1 . The reaction rate was dependent upon the concentration of protein S. Protein S alone, in the absence of APC, had no effect on the Factor 100`- (Fig. 2) . No differences were observed when protein S was included in the reaction mixture. High molecular weight bands ranging from 90,000 to 180,000 (the Factor VIII heavy chain [23] ) were degraded, while the M, 80,000 light chain band remained intact. A predominant cleavage product of Mr 43,000 was observed. Also, minor fragments of Mr 21,000 and Mr 49,000 were formed, the first being more prominent in the presence of protein S and the latter being further degraded. Although the coagulant activity had disappeared, a small portion of the Mr 90,000-180,000 bands ofthe radiolabeled preparation remained intact, which may be an artifact due to the labeling procedure.
The inactivation of purified Factor VIII was compared to the inactivation of the reconstituted Factor VIII-von Willebrand factor complex (Fig. 3) (Fig. 4 A) , resulting in a 90% inhibition of the Factor VIII activity in 15 min. Addition ofan extra amount ofprotein S (22 nM) to the plasma enhanced the reaction, resulting in a 95% inhibition in 15 min. In contrast, when Factor VIII was present as a complex with von Willebrand factor, the inactivation by APC was much slower, resulting in a 25% inhibition in 15 min. Addition of extra protein S had no effect on this reaction. In hemophilic plasma, which expressed an almost normal von Willebrand factor content, this protective effect was even more pronounced (Fig. 4 B) (14, 15) . In the absence of protein S, APC did not inactivate Factor VIII (Fig. 5 ). When purified protein S was added back to the plasma (final concentration 22 nM), the inactivation of Factor VIII was completely restored. A mixing experiment with hemophilia A and von Willebrand's disease plasmas was performed to determine the amount of von Willebrand factor needed to protect Factor VIII from inactivation by APC (Fig. 6) . A final concentration of 0.3 VWF:Ag U/ml was needed for complete protection of Factor VIII (0.2 U/ml) at an APC concentration of 16 nM, suggesting that at least a 1:1 ratio on a unit basis of von Willebrand factor to Factor VIII is needed to fully incorporate Factor VIII in a protective complex.
To assess whether Factor VIII did indeed form a complex with von Willebrand factor after reconstitution, we mixed purified von Willebrand factor with increasing amounts of purified Factor VIII and subjected the mixture to gelfiltration using Sepharose CL-4B. Factor VIII coeluted with von Willebrand factor in the void volume of the column (4.2 ml) even when the von Willebrand factor concentration was only 18% of the Factor VIII concentration (based on units) ( Table I ). The recovery of Factor VIII in the void volume was 85% and was not correlated to the amount of von Willebrand factor. Purified Factor VIII in the absence of von Willebrand factor eluted in the included volume (8.1 ml) of the column with a recovery of 27%. Subsequent treatment of the Factor VIII-containing fractions with APC showed that although all time (min) Figure 5 . Inactivation of Factor VIII in von Willebrand's disease plasma depleted of protein S. APC (4 nM) was added to plasma containing Factor VIII (0.2 U/ml, solid symbols) or Factor VIII may be bound to von Willebrand factor, this does not provide maximal protection against APC. For example, only 32% of the Factor VIII activity remained after 10 min treatment with APC when Factor VIII was present in a 5.6-fold excess over von Willebrand factor. In the presence ofa 3.7-fold excess of von Willebrand factor, 89% of the Factor VIII activity was retained (Table I) .
To investigate whether full multimerization of von Willebrand factor is a prerequisite for protection of Factor VIII, we added APC to various plasmas of five patients with type IIA von Willebrand's disease. The results (Table II) demonstrate that if the VWF:Ag to Factor VIII ratio is more than one (on the basis of units), there is little inactivation of Factor VIII. Therefore, high and low molecular weight forms of von Willebrand factor seem to be equally potent in protecting Factor VIII against proteolysis by APC. When the Factor VIII concentration in the plasma of one patient (E.) was increased by adding purified Factor VIII, the same percentage of activity (80%) remained after 20 min of incubation with APC, indicating that endogenous and exogenous Factor VIII are equally well protected.
Since Factor V is also a substrate for APC, we wished to demonstrate that the protective effect of von Willebrand factor is specific for Factor VIII. For this purpose, plasma from a patient with severe von Willebrand's disease, which contained 72% ofthe normal Factor V concentration, was incubated with APC (30 nM). Fig. 7 shows that the inactivation ofFactor V in plasma was not influenced by the addition of von Willebrand factor (14 U/ml).
Discussion
The studies presented in this report have focussed on two aspects of the inactivation of Factor VIII by activated protein The reaction rate of Factor VIII inactivation was enhanced ninefold in the presence of protein S. The same effect was seen when thrombin-activated Factor VIII was used (results not shown). Similarly, Walker (13) observed a fivefold increase of the Factor Va inactivation by APC. The importance of protein S as an anticoagulant protein has been inferred from the inability of APC to prolong the clotting time of protein S-deficient plasma (15, 37) and from the high risk ofthrombosis that results from a protein S deficiency (15, (38) (39) (40) . Although APC can inactivate purified Factor VIII in the absence of protein S (Figs. 1, 2 , and 3 [5] [6] [7] ), we found no inactivation of Factor VIII in von Willebrand's disease plasma from which protein S was removed (Fig. 5) . Moreover, addition of extra protein S to plasma which expressed a normal protein S content, enhanced the effect of APC (Fig. 4 A) . During the incubation, the concentration of plasma-derived, free protein S (i.e., not complexed to C4b-binding protein) would have been -66 nM (41) , which is a 16-fold excess over the amount ofAPC that we added to this plasma. Moreover, comparison ofFigs. 1 and 4 A shows that in plasma the reaction rate decreases during the incubation, although only 10% of the APC activity was lost. It seems that APC and protein S function less efficiently in plasma than in a purified system, perhaps because the pro- In plasma, Factor VIII circulates in a complex with von Willebrand factor. We found that in the presence of von Willebrand factor, Factor VIII is protected against APC. This effect is specific for Factor VIII, since the inactivation of Factor V in plasma was not affected by von Willebrand factor (Fig. 7) . Although Factor VIII binds to von Willebrand factor through its carboxy-terminal light chain (42) , and APC inactivates Factor VIII by proteolytic cleavage of the amino-terminal heavy chain, it cannot be excluded that von Willebrand factor shields offthe cleavage site for APC, or alternatively, induces a conformational change in the Factor VIII molecule that makes the cleavage site less accessible. Another possible explanation is derived from analogies with Factor Va. Like Factor VIII, Factor Va is inactivated by APC by cleavage ofthe heavy chain in the presence ofphospholipids (3, 43) . The light chain, which contains the binding site of Factor Va for phospholipids (44) is needed for this reaction (3). Accordingly, von Willebrand factor could prevent the formation of a Factor VIII-phospholipid-APC complex by inhibiting the binding of Factor VIII to phospholipids. A competition between von Willebrand factor and phospholipids for Factor VIII has been demonstrated (45, 46), and we have observed a diminished binding of factor VIII-light chain to von Willebrand factor in the presence of phospholipids (Hamer, R., and J. Koedam, unpublished observation). Recently, the light chain of Factor VIII was reported to contain the phospholipid binding site (47). It is also noteworthy that the inactivation of the Factor VIII-von Willebrand factor complex by APC is not influenced by protein S (Figs. 3, 4 A, and 5) . Possibly, the binding of the protein S-APC-phospholipid complex to Factor VIII is inhibited by von Willebrand factor. Studies to further characterize these interactions are in progress.
By varying the amount of von Willebrand factor in plasma in the presence of constant amounts of Factor VIII and APC, we have shown that a one to one ratio ofvon Willebrand factor to Factor VIII (based on units) is needed in order to obtain full protection. von Willebrand factor exists in plasma as a series of multimers (48, 49) composed of a subunit of M, 270,000. In normal plasma, this subunit is present in an -100-fold molar excess over Factor VIII (assuming an M, of 270,000 for Factor VIII and concentrations of 10 and 0.1 tg/ml for von Wiflebrand factor and Factor VIII, respectively). Multimers of high molecular weight as well as of low molecular weight have been shown to express coagulant activity and thus bind Factor VIII (50, 51). We used gel filtration to demonstrate binding of Factor VIII to von Willebrand factor. As much as 5.6 U of Factor VIII eluted with 1 U of von Willebrand factor in the void volume of the column (Table II) . Similarly, Zucker et al. (52) have shown that von Willebrand factor in plasma can be loaded with at least 12 times the amount of Factor VIII that is normally present. In spite of this excess of apparent binding sites on von Willebrand factor for Factor VIII, there exists a close correlation between the concentrations of the two proteins in normals and in many disease states (53, 54) . The study ofWeiss et al. (26) demonstrated an increased lability ofFactor VIII especially in those plasmas which expressed a Factor VIII/von Willebrand factor ratio of more than one. These observations support our finding that although 1 U of von Willebrand factor may bind more than one unit Factor VIII, a 1:1 ratio as found in normal plasma is needed for full protection against proteolysis (Fig. 6 , Table II ). The mechanism underlying this apparent discrepancy between binding and protection of Factor VIII by von Willebrand factor is under current investigation. The normal resistance of Factor VIII to APC in patients with type IIA von Willebrand's disease (Table II) is in favor of a quantitative rather than a qualitative (i.e., high degree of multimerization) requirement of von Willebrand factor for protection of Factor VIII.
In conclusion, our results suggest that APC may function locally at sites where Factor VIII has been activated, but is not responsible for the catabolism of Factor VIII that circulates in a complex with von Willebrand factor.
